| 主权项 |
1. A method of evaluating or treating a subject, comprising:
a) optionally, acquiring a subject sample; b) acquiring a value or values that is a function of the level of gene expression for (each of) a plurality of genes selected from a first and/or second and/or third and/or fourth and or/fifth and/or sixth set of genes, wherein
(i) said first set of genes comprises or consists of:S100A4, SDC2, CYP1B1, FERMT2, CYBRD1, SNAI2, CD44, BIN1, PMP22, CTGF, IGFBP3, ANXA6, MAP1B, TAGLN, ENPP2, FBLN5, PCOLCE, FN1, VIM, PPAP2B, SEM5A, VCAN, NID2, NID1, HAS2, PRRX1, TNFAIP6, CLDN4, FADS2, DDIT4, GNG11, PER1, ISCU, KPNA3, SLC44A1, FKBP5, NR2F1, MLPH, DOCK10, RGS4, IGFBP4; and(ii) said second set of genes comprises or consists of:S100A4, SDC2, CYP1B1, FERMT2, CYBRD1, SNAI2, CD44, BIN1, ENPP2, FBLN5, PCOLCE, FN1, VIM, PPAP2B, SEM5A, VCAN, CLDN4, FADS2, DDIT4, GNG11, PER1, ISCU, KPNA3, SLC44A1, FKBP5, IGFBP4; and(iii) said third set of genes comprises or consists of:SDC2, CYBRD1, SNAI2, PMP22, CTGF, IGFBP3, ANXA6, MAP1B, TAGLN, PPAP2B, HAS2, NRF2, MLPH, DOCK10, RGS4; and(iv) said fourth set of genes comprises or consists of:FERMT2, BIN1, PMP22, CHN1, CTGF, IGFBP3, NID2, CLDN4, CYBRD1, PRR16, ANXA6, PCOLCE, PPAP2B, HAS2, CDH11, MLPH, DOCK10, RGS4, PVRL3, NID2, SLC44A1, FKBP5; and(v) said fifth set of genes comprises or consists of:FERMT2, BIN1, PMP22, CHN1, CTGF, IGFBP3, NID2, CLDN4; and(vi) said sixth set of genes comprises or consists of:HAS2, BIN1, PCOLCE, FERMT2, CTGF, IGFBP3, NID2, SLC44A1, FKBP5, and MLPH; and (c) responsive to said value or values:
(i) classifying said subject; or(ii) administering treatment comprising an agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells, to said subject; provided that, if (c)(ii) is not performed the acquisition in (a) or (b) comprises directly acquiring; thereby evaluating or treating said subject. |
